<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED50 for this effect is 5-30 pg/mL.
The specific activity of Recombinant Human IFN-beta is approximately 2.8 x 108 IU/mg, which is calibrated against human IFN- beta WHO International Standard (NIBSC code: 00/572).
Source
Chinese Hamster Ovary cell line, CHO-derived Met22-Asn187
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
8499-IF
8499-IF/CF
Formulation Lyophilized from a 0.2 μm filtered solution in Citric Acid and CHAPS with BSA as a carrier protein.
Formulation Lyophilized from a 0.2 μm filtered solution in Citric Acid and CHAPS.
Reconstitution Reconstitute at 200 μg/mL in sterile water.
Reconstitution Reconstitute at 200 μg/mL in sterile water.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Recombinant Human IFN‑ beta (Catalog # 8499-IF) exhibits anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 5-30 pg/mL.
Background: IFN-beta
Interferon beta (IFN-beta ), also known as fibroblast IFN, is a secreted, approximately 22 kDa member of the type I interferon family of molecules (1). Mature human IFN-beta shares 47% and 46% amino acid sequence identity with the mouse and rat proteins, respectively. Fibroblasts are the major producers of IFN-beta, but it can also be produced by dendritic cells, macrophages, and endothelial cells in response to pathogen exposure (2). It is transcriptionally regulated by TRAF3, IRF3, IRF7, and NF-kappa B (3, 4). Following secretion, IFN-beta signals through the heterodimeric IFN-alpha / beta Receptor and activates the JAK/STAT signaling pathway (5-8). IFN-beta -deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis (EAE), a disease model of human multiple sclerosis (MS) (9). Furthermore, IFN-beta has been shown to suppress the Th17 cell response in both MS and EAE and has commonly been used as a treatment for MS (10-14).
References:
González-Navajas, J.M. et al. (2012) Nat. Rev. Immunol. 12:125.
Reder, A.T. and X. Feng (2013) Front. Immunol. 4:281.
Schafer, S.L. et al. (1998) J. Biol. Chem. 273:2714.
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED50 for this effect is 5-30 pg/mL.
The specific activity of Recombinant Human IFN-beta is approximately 2.8 x 108 IU/mg, which is calibrated against human IFN- beta WHO International Standard (NIBSC code: 00/572).
Source
Chinese Hamster Ovary cell line, CHO-derived Met22-Asn187
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
8499-IF
8499-IF/CF
Formulation Lyophilized from a 0.2 μm filtered solution in Citric Acid and CHAPS with BSA as a carrier protein.
Formulation Lyophilized from a 0.2 μm filtered solution in Citric Acid and CHAPS.
Reconstitution Reconstitute at 200 μg/mL in sterile water.
Reconstitution Reconstitute at 200 μg/mL in sterile water.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
Recombinant Human IFN‑ beta (Catalog # 8499-IF) exhibits anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 5-30 pg/mL.
Background: IFN-beta
Interferon beta (IFN-beta ), also known as fibroblast IFN, is a secreted, approximately 22 kDa member of the type I interferon family of molecules (1). Mature human IFN-beta shares 47% and 46% amino acid sequence identity with the mouse and rat proteins, respectively. Fibroblasts are the major producers of IFN-beta, but it can also be produced by dendritic cells, macrophages, and endothelial cells in response to pathogen exposure (2). It is transcriptionally regulated by TRAF3, IRF3, IRF7, and NF-kappa B (3, 4). Following secretion, IFN-beta signals through the heterodimeric IFN-alpha / beta Receptor and activates the JAK/STAT signaling pathway (5-8). IFN-beta -deficient mice show increased susceptibility to experimental autoimmune encephalomyelitis (EAE), a disease model of human multiple sclerosis (MS) (9). Furthermore, IFN-beta has been shown to suppress the Th17 cell response in both MS and EAE and has commonly been used as a treatment for MS (10-14).
References:
González-Navajas, J.M. et al. (2012) Nat. Rev. Immunol. 12:125.
Reder, A.T. and X. Feng (2013) Front. Immunol. 4:281.
Schafer, S.L. et al. (1998) J. Biol. Chem. 273:2714.